Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE. Balsat M, et al. Among authors: legros l. Leuk Res. 2023 Jul;130:107308. doi: 10.1016/j.leukres.2023.107308. Epub 2023 May 9. Leuk Res. 2023. PMID: 37230027
[Radiotherapy in primary cerebral lymphoma].
Legros L, Benezery K, Lagrange JL. Legros L, et al. Cancer Radiother. 1999 Mar-Apr;3(2):149-53. doi: 10.1016/S1278-3218(99)80045-6. Cancer Radiother. 1999. PMID: 10230374 Review. French.
Mechanism of action of the multikinase inhibitor Foretinib.
Dufies M, Jacquel A, Robert G, Cluzeau T, Puissant A, Fenouille N, Legros L, Raynaud S, Cassuto JP, Luciano F, Auberger P. Dufies M, et al. Among authors: legros l. Cell Cycle. 2011 Dec 1;10(23):4138-48. doi: 10.4161/cc.10.23.18323. Epub 2011 Dec 1. Cell Cycle. 2011. PMID: 22101270
Are nilotinib-associated vascular adverse events an under-estimated problem?
Stève-Dumont M, Baldin B, Legros L, Thyss A, Re D, Rocher F, Ajmia F, Spreux A, Drici MD. Stève-Dumont M, et al. Among authors: legros l. Fundam Clin Pharmacol. 2015 Apr;29(2):204-8. doi: 10.1111/fcp.12102. Epub 2015 Mar 11. Fundam Clin Pharmacol. 2015. PMID: 25619238
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S. Santini V, et al. Among authors: legros l. Blood. 2013 Sep 26;122(13):2286-8. doi: 10.1182/blood-2013-07-512442. Blood. 2013. PMID: 24072851 Free article. No abstract available.
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M, Guilhot F, Legros L, Maloisel F, Kiladjian JJ, Mahon FX, Lê QH, Michallet M, Roche-Lestienne C, Preudhomme C. Nicolini FE, et al. Among authors: legros l. Haematologica. 2007 Sep;92(9):1238-41. doi: 10.3324/haematol.11369. Haematologica. 2007. PMID: 17768119 Free article.
Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy.
Lippert E, Etienne G, Mozziconacci MJ, Laibe S, Gervais C, Girault S, Gachard N, Tigaud I, Dastugue N, Huguet F, Fort MP, Legros L, Eclache V, Mahon FX. Lippert E, et al. Among authors: legros l. Haematologica. 2010 Sep;95(9):1604-7. doi: 10.3324/haematol.2009.019109. Epub 2010 Apr 30. Haematologica. 2010. PMID: 20435623 Free PMC article.
157 results